# Juno Therapeutics

Juno Therapeutics is an Asset Manager based in Seattle, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Seattle, United States
- **Region:** North America
- **Address:** Seattle, WA, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** junotherapeutics.com

## Regulatory record

- **Reports private funds:** No

## About

Juno Therapeutics is a clinical-stage biotechnology company based in Seattle, United States, founded in 2013. It develops immunotherapies for cancer treatment. The company has secured $310 million in total funding.

## Sectors

- Biotechnology
- Immuno-Oncology
- Cell Therapy
- Healthcare

## People

- Hans Bishop — Chief Executive Officer (co-founder)
- Larry Corey — Co-founder
- Cary Pfeffer — Co-founder
- Mark J. Litton — Co-founder

## Questions

### Who ran investment decisions at Juno Therapeutics?

Hans Bishop served as CEO from founding in 2013 through the acquisition. The venture investors, including Arch Venture Partners and Flagship Ventures, held board seats and influenced strategic funding decisions (per SEC filings, 2014).

### What investment stages did Juno typically target?

Juno targeted drug development from preclinical research through Phase 2 clinical trials. It did not act as an investor but as a biotech firm conducting clinical-stage work (per FDA clinical trial registries).

### Which sectors did Juno avoid?

Juno focused exclusively on oncology cell therapies and did not materially engage in other therapeutic areas, medical devices, or diagnostics (per clinical trial data).

## Related profiles

- [PC Ventures](https://altss.com/profile/pc-ventures)
- [Reignwood Group](https://altss.com/profile/reignwood-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/juno-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology